Epstein-Barr virus nuclear antigen 1: From immunologically invisible to a promising T cell target

Journal of Experimental Medicine

Volumn 199, Issue 10, 2004, Pages 1301-1304

  Münz, Christian ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL NUCLEUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CELL PROLIFERATION; CELLULAR IMMUNITY; EPSTEIN BARR VIRUS; IMMUNE ESCAPE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; VIRUS INFECTION; VIRUS LATENCY;

EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; T-LYMPHOCYTES;

EID: 2542481857     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20040730     Document Type: Review

References (30)

1. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell. 77:791-793.
2. Babcock, G.J., L.L. Decker, M. Volk, and D.A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity. 9:395-404.
3. Kieff, E., and A. Rickinson. 2001. Epstein-Barr Virus and its replication. In Fields Virology. D.M. Knipe and P.M. Howley, editors. Lippincott-Raven, Philadelphia, PA. 2511-2573.
4. Rickinson, A.B., and E. Kieff. 2001. Epstein-Barr Virus. In Fields Virology. P.M. Knipe and P.M. Howley, editors. Lippincott-Raven, Philadelphia, PA. 2575-2627.
5. Humme, S., G. Reisbach, R. Feederle, H.J. Delecluse, K. Bousset, W. Hammerschmidt, and A. Schepers. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA. 100:10989-10994.
6. Hochberg, D., J.M. Middeldorp, M. Catalina, J.L. Sullivan, K. Luzuriaga, and D.A. Thorley-Lawson. 2004. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. USA. 101:239-244.
7. Rowe, M., R. Khanna, C.A. Jacob, V. Argaet, A. Kelly, S. Powis, M. Belich, D. Croom-Carter, S. Lee, S.R. Burrows, et al. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374-1384.
8. Chen, F., J.Z. Zou, L. di Renzo, G. Winberg, L.F. Hu, E. Klein, G. Klein, and I. Ernberg. 1995. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69:3752-3758.
9. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 7:791-802.
10. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M.G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94:12616-12621.
11. Yin, Y., B. Manoury, and R. Fahraeus. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 301:1371-1374.
12. Khanna, R., S.R. Burrows, P.M. Steigerwald-Mullen, D.J. Moss, M.G. Kurilla, and L. Cooper. 1997. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 9:1537-1543.
13. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191:1649-1660.
14. + T-helper 1 responses. J. Virol. 75:8649-8659.
15. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J. Clin. Invest. 107:121-130.
16. + Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593-1603.
17. + T cells. Cancer Res. 62:7195-7199.
18. +-T-cell clones reactive to EBNA1 inhibit Epstein-Barr Virus-induced B-cell proliferation. J. Virol. 77:12088-12104.
19. + T lymphocytes. J. Exp. Med. 199:459-470.
20. Lee, S.P., J.M. Brooks, H. Al-Jarrah, W.A. Thomas, T.A. Haigh, G.S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J.L. Yates, et al. CD8 T cell recognition of endogenously expressed EBNA1: a reappraisal of protection mediated by the glycine-alanine repeat. J. Exp. Med. 199:1409-1420.
21. + T cell epitopes from Epstein-Barr virus encoded nuclear antigen 1: functional evidence for DRiPs as a source of endogenously processed epitopes. J. Exp. Med. 199:1421-1431.
22. + T cells that poorly kill EBV-infected cells. Viral Immunol. 15:213-225.
23. + T cell recognition. J. Biol. Chem. 276:33353-33360.
24. Schubert, U., L.C. Anton, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:770-774.
25. Bickham, K., K. Goodman, C. Paludan, S. Nikiforow, M.L. Tsang, R.M. Steinman, and C. Münz. 2003. Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro. J. Exp. Med. 198:1653-1663.
26. Henle, W., G. Henle, J. Andersson, I. Ernberg, G. Klein, C.A. Horwitz, G. Marklund, L. Rymo, C. Wellinder, and S.E. Straus. 1987. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl. Acad. Sci. USA. 84:570-574.
27. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380.
28. Rooney, C.M., L.K. Aguilar, M.H. Huls, M.K. Brenner, and H.E. Heslop. 2001. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr. Top. Microbiol. Immunol. 258:221-229.
29. + T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62:6952-6958.
30. +-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. 78:768-778.